These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841 [TBL] [Abstract][Full Text] [Related]
3. Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. Glöckner F; Meske V; Lütjohann D; Ohm TG J Neuropathol Exp Neurol; 2011 Apr; 70(4):292-301. PubMed ID: 21412171 [TBL] [Abstract][Full Text] [Related]
4. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Zhang Q; Zhang X; Sun A Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923 [TBL] [Abstract][Full Text] [Related]
5. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
6. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. Distl R; Treiber-Held S; Albert F; Meske V; Harzer K; Ohm TG J Pathol; 2003 May; 200(1):104-11. PubMed ID: 12692848 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. Köhler C; Bista P; Götz J; Schröder H Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372 [TBL] [Abstract][Full Text] [Related]
8. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886 [TBL] [Abstract][Full Text] [Related]
9. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. García-Cabrero AM; Guerrero-López R; Giráldez BG; Llorens-Martín M; Avila J; Serratosa JM; Sánchez MP Neurobiol Dis; 2013 Oct; 58():200-8. PubMed ID: 23774255 [TBL] [Abstract][Full Text] [Related]
10. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Lewis J; McGowan E; Rockwood J; Melrose H; Nacharaju P; Van Slegtenhorst M; Gwinn-Hardy K; Paul Murphy M; Baker M; Yu X; Duff K; Hardy J; Corral A; Lin WL; Yen SH; Dickson DW; Davies P; Hutton M Nat Genet; 2000 Aug; 25(4):402-5. PubMed ID: 10932182 [TBL] [Abstract][Full Text] [Related]
11. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. Treiber-Held S; Distl R; Meske V; Albert F; Ohm TG J Pathol; 2003 May; 200(1):95-103. PubMed ID: 12692847 [TBL] [Abstract][Full Text] [Related]
12. Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice. Morcinek K; Köhler C; Götz J; Schröder H Brain Res; 2013 Feb; 1497():73-84. PubMed ID: 23261664 [TBL] [Abstract][Full Text] [Related]
13. Modulation of tau pathology in tau transgenic models. Brion JP; Ando K; Heraud C; Leroy K Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992 [TBL] [Abstract][Full Text] [Related]
14. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. Ferrer I; López-González I; Carmona M; Arregui L; Dalfó E; Torrejón-Escribano B; Diehl R; Kovacs GG J Neuropathol Exp Neurol; 2014 Jan; 73(1):81-97. PubMed ID: 24335532 [TBL] [Abstract][Full Text] [Related]
15. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810 [TBL] [Abstract][Full Text] [Related]
16. Effects of alpha-tocopherol on an animal model of tauopathies. Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189 [TBL] [Abstract][Full Text] [Related]
17. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Padmanabhan J; Levy M; Dickson DW; Potter H Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690 [TBL] [Abstract][Full Text] [Related]
19. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146 [TBL] [Abstract][Full Text] [Related]
20. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]